Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update! Now will be looking for data.

$Ocugen (OCGN.US)$ Ocugen Announces Completion of Dosing in Subjects With Stargardt Disease in High Dose Cohort of Phase 1/2 Gardian Clinical Trial of Ocu410St—a Modifier Gene Therapy
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
+0
Translate
Report
11K Views
Comment
Sign in to post a comment